Publications by authors named "Francesco Salonne"
Article Synopsis
- - Recent advancements in ccRCC treatment contrast with the limited research and improvements in non-clear cell renal cell carcinoma (nccRCC) therapies, highlighting a gap in understanding these cancer types.
- - The 2022 WHO classification has redefined key nccRCC subtypes and introduced a molecular classification, which paves the way for better profiling and targeted therapies.
- - The study reviews genomic alterations in nccRCC that could inform treatment options and emphasizes the need for personalized medicine due to the diverse nature of these cancers, as well as ongoing clinical trials for further insights.
Clear cell renal cell carcinoma (ccRCC) treatment has undergone three major paradigm shifts in recent years, first with the introduction of molecular targeted therapies, then with immune checkpoint inhibitors, and, more recently, with immune-based combinations. However, to date, molecular predictors of response to targeted agents have not been identified for ccRCC. The WHO 2022 classification of renal neoplasms introduced the molecularly defined RCC class, which is a first step in the direction of a better molecular profiling of RCC.
View Article and Find Full Text PDF